The Asia Pacific Endoluminal Suturing Devices Market would witness market growth of 13.0% CAGR during the forecast period (2022-2028).
Morbid obesity can only be treated with surgery, which consists of restriction operations (sleeve gastrectomy) and malabsorptive surgeries (bypass surgery). The good medical practice guidelines recommend bariatric surgery for individuals with body mass indexes (BMIs) over 40kg/m2 without co-morbidities or between 35 and 40kg/m2 with co-morbidities.
For obese patients with a BMI between 30 and 35 kg/m2 with or without comorbidities (Class I) or between 35 and 40 kg/m2 without comorbidity, bariatric surgery is currently not an option (Class II without comorbidity). Currently, the only option for interventional treatment for patients with obesity of class I or class II without co-morbidity is nutritional therapy.
A cutting-edge surgical technique for lowering stomach capacity is vertical gastric plication (without cutting the gastric wall). Because operations are becoming less and less invasive, a transoral or endoluminal approach (i.e., a surgery that doesn't require an incision because access is allowed through the mouth) may provide some extra advantages to the patient. Clinicians can now start investigating flexible endoscopy-based bariatric surgeries because of advancements in endoluminal technology.
Due to the region's expanding healthcare infrastructure and a sizable population that is susceptible to several chronic diseases, Asia Pacific is predicted to experience the quickest growth in the endoluminal suturing device market. The rise of gastrointestinal disease across the region is being attributed to reasons such as growing urbanization, shifting environmental conditions, and changing lifestyles. Additionally, because of the rise in chronic and infectious diseases, minimally invasive operations are in great demand in emerging countries like China and India.
The China market dominated the Asia Pacific Endoluminal Suturing Devices Market by Country in 2021; thereby, achieving a market value of $10.8 million by 2028. The Japan market is estimated to witness a CAGR of 12.3% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 13.7% during (2022 - 2028).
Based on Application, the market is segmented into Gastrointestinal Surgery, Bariatric Surgery, Gastroesophageal Reflux Disease Surgery and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Clinics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Endoluminal Suturing Devices Market is Projected to reach USD 152.3 Million by 2028, at a CAGR of 12%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Apollo Endosurgery, Inc., Johnson & Johnson, Medtronic PLC, Cook Medical, Inc. (Cook Group), USGI Medical, Ovesco Endoscopy AG, Endo Tools Therapeutics S.A., ErgoSuture, Suture Ltd.
By Application
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 